#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Haemolytic uraemic syndrome Acute myeloid leukaemia recurrent Fragile X syndrome Pustular psoriasis Gaucher's disease type I Non-small cell lung cancer Oropharyngeal cancer recurrent Epidermolysis bullosa Hydrocephalus Scleroderma associated digital ulcer Basal cell naevus syndrome Acute leukaemia Hairy cell leukaemia recurrent Chronic graft versus host disease Thymic carcinoma More trials…

    Learn about Rare Diseases

    Hereditary angioedema with C1 esterase inhibitor deficiency Idiopathic inflammatory myopathy – Diagnostics Primary immunodeficiency syndrome – Treatment Hyperoxaluria – Trials in Disease Bronchopulmonary dysplasia Atypical teratoid/rhabdoid tumour of CNS – Trials in Disease Piriformis syndrome – Life with Disease Medulloblastoma Hepatoblastoma – Basic Information Activated PI3 kinase delta syndrome – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Deoxyribonucleic Acid Petrelintide Crofelemer GSKVX000000030825 Bi 1839100 ALE.P02 Lidocaine Magnesium Crizanlizumab Copper (64Cu) Chloride Mianserin Hydrochloride Sodium Thiosulfate Octreotide Hydrochloride Specific Nucleic Acid Sna-Ebv Follitropin Beta Deferoxamine Epirubicin Imatinib Interferon Beta-1B Captopril More therapies…

    Learn about Your Condition

    Progressive supranuclear palsy Acute myocardial infarction Mucopolysaccharidosis II Pancreatic neoplasm Bladder cancer recurrent Appendicitis perforated Hepatitis alcoholic Foot deformity Metastasis Lupus nephritis Wheezing Malignant melanoma of eyelid Gaucher's disease type I Fungal infection Epiphysiolysis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Neoplasm

  • Study on the Safety and Tolerability of TransCon IL-2 β/γ, Pembrolizumab, and Chemotherapy in Adults with Advanced or Metastatic Solid Tumors

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Neoplasm
    Investigated Drugs:
    • Acp-017
    • Transcon Il-2Β/Γ
    • Pembrolizumab
    Belgium Italy Poland Spain

  • Study of BMS-986288 and Nivolumab for Patients with Advanced Solid Tumors

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Neoplasm
    Investigated Drugs:
    • Bms-986288
    • Regorafenib
    • Nivolumab
    France Italy Spain

  • Study of Pembrolizumab for Patients with Advanced Solid Tumors

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Pembrolizumab
    Denmark France Germany Italy The Netherlands Norway +3

  • Study of MK-1088 and Pembrolizumab for Patients with Advanced Solid Tumors

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Neoplasm
    Investigated Drugs:
    • Mk-1088
    • Pembrolizumab
    Denmark

  • Study of CFT1946 alone and with trametinib or cetuximab in patients with BRAF-V600 mutant solid tumors who have received standard treatment

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Neoplasm
    Investigated Drugs:
    • Cft1946
    • Cetuximab
    • Trametinib
    France Germany Italy Spain

  • Study of BMS-986408 Alone or with Nivolumab and Ipilimumab for Patients with Advanced Solid Tumors

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Neoplasm
    Investigated Drugs:
    • Bms-986408
    • Ipilimumab
    • Nivolumab
    France Spain
Previous Page
1 … 21 22 23 24 25
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!